Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H1 2012

Peripheral Neuropathy (Sensory Neuropathy) – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H1 2012', provides an overview of the Peripheral Neuropathy (Sensory Neuropathy) therapeutic pipeline. This report provides information on the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy). 'Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Peripheral Neuropathy (Sensory Neuropathy).
- A review of the Peripheral Neuropathy (Sensory Neuropathy) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Peripheral Neuropathy (Sensory Neuropathy) pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Peripheral Neuropathy (Sensory Neuropathy).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Peripheral Neuropathy (Sensory Neuropathy) pipeline depth and focus of Peripheral Neuropathy (Sensory Neuropathy) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Peripheral Neuropathy (Sensory Neuropathy) Therapeutic Products under Development, Key Players in Peripheral Neuropathy (Sensory Neuropathy) Therapeutics, Peripheral Neuropathy (Sensory Neuropathy) Pipeline Overview, Peripheral Neuropathy (Sensory Neuropathy) Pipeline, Peripheral Neuropathy (Sensory Neuropathy) Pipeline Assessment SHOW LESS READ MORE >

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Peripheral Neuropathy (Sensory Neuropathy) Overview
Therapeutics Development
An Overview of Pipeline Products for Peripheral Neuropathy (Sensory Neuropathy)
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics under Development by Companies
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics – Products under Development by Companies
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Peripheral Neuropathy (Sensory Neuropathy) Therapeutics Development
NsGene A/S
Bayer AG
Allon Therapeutics Inc.
Spectrum Pharmaceuticals, Inc.
CeNeRx BioPharma, Inc.
Peripheral Neuropathy (Sensory Neuropathy) – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
SPI-205 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AL-309 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NsG31 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Marijuana - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Amifostine trihydrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Amifostine Trihydrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sagopilone + Acetyl-L-Carnitine + Prednisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Amitriptyline + Ketamine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Glutamine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CXB040 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CXB070 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Glutathione + Paclitaxel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Duloxetine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pregabalin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CXB006 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CNSB015 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics – Drug Profile Updates
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics – Discontinued Products
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics - Dormant Products
Peripheral Neuropathy (Sensory Neuropathy) – Product Development Milestones
Featured News & Press Releases
Feb 09, 2011: CeNeRx Receives FDA IND Approval For CXB909
Feb 07, 2011: EpiCept Reports Positive Results From EpiCept NP-1 Trial In Patients With Chemotherapy-Induced Peripheral Neuropathy
Sep 08, 2010: DARA Announces Phase III Trial Results Of KRN5500 In Patients With Chemotherapy Induced Peripheral Neuropathy And Advanced Cancer
Jun 11, 2010: Pfizer, Eisai to launch postherpetic neuralgia drug Lyrica Capsules on June 22
Jun 11, 2010: Pfizer, Eisai to launch postherpetic neuralgia drug Lyrica Capsules on June 22
May 28, 2010: Relevare Pharmaceuticals Presents Latest Clinical Trial Data On CNSB015 At Third International Congress On Neuropathic Pain In Athens, Greece
Apr 06, 2010: Pfizer told to Pay $142.1 million for Neurontin marketing violations.
Dec 20, 2009: CNSBio Inc. To Present Latest Clinical Trial Data For CNSB015 At Neuropathic Pain Conference in San Francisco
Nov 18, 2009: NeoPharm Presents LE-DT Phase I Data At The AACR Conference
Oct 14, 2009: Newron Returns Rights to HF0420
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Peripheral Neuropathy (Sensory Neuropathy), H1 2012
Products under Development for Peripheral Neuropathy (Sensory Neuropathy) – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
NsGene A/S, H1 2012
Bayer AG, H1 2012
Allon Therapeutics Inc., H1 2012
Spectrum Pharmaceuticals, Inc., H1 2012
CeNeRx BioPharma, Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics – Drug Profile Updates
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics – Discontinued Products
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Peripheral Neuropathy (Sensory Neuropathy), H1 2012
Products under Development for Peripheral Neuropathy (Sensory Neuropathy) – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012